Gina Vaccaro

Associate Professor

Associate Professor, Knight Cancer Institute

Emailvaccarog@ohsu.edu

285 Citations
9 h-Index

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

25 Similar Profiles

Esophageal Neoplasms Medicine & Life Sciences

Survival Medicine & Life Sciences

Neoadjuvant Therapy Medicine & Life Sciences

Chemoradiotherapy Medicine & Life Sciences

Hepatocellular Carcinoma Medicine & Life Sciences

Adenocarcinoma Medicine & Life Sciences

Esophagectomy Medicine & Life Sciences

Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

285 Citations
9 h-Index
18 Article
2 Review article

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Kearney, M. R., Chen, E. Y., Vaccaro, G., Strother, J., Burt, A., Todd, K., Donovan, J., Kampa-Schittenhelm, K. M. & Lopez, C., Jan 1 2019, In : Anticancer Research. 39, 1, p. 245-252 8 p.

Research output: Contribution to journal › Article

irinotecan

Colorectal Neoplasms

oxaliplatin

Neutropenia

Combination Drug Therapy

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design

Moehler, M., Ryu, M. H., Dvorkin, M., Lee, K. W., Coşkun, H., Wong, R., Chung, H. C., Poltoratsky, A., Tsuji, A., Yen, C. J., Muntean, A. S., Le Sourd, S., Vaccaro, G., Overton, L., Boku, N., Wainberg, Z. A., Patel, M., Sharma, M., Xiong, H., Conti, I. & 2 othersTaieb, J. & Bang, Y. J., Feb 1 2019, In : Future Oncology. 15, 6, p. 567-577 11 p.

Research output: Contribution to journal › Article

Stomach Neoplasms

Esophagogastric Junction

Stomach

oxaliplatin

Maintenance

76 Citations (Scopus)

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

KEYNOTE-224 investigators, Jul 1 2018, In : The Lancet Oncology. 19, 7, p. 940-952 13 p.

Research output: Contribution to journal › Article

Hepatocellular Carcinoma

pembrolizumab

sorafenib

Therapeutics

Disease Progression

15 Citations (Scopus)

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Abou-Alfa, G. K., Qin, S., Ryoo, B. Y., Lu, S. N., Yen, C. J., Feng, Y. H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M., Ma, J. & 7 othersWan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C. C., Chao, Y. & Chen, L. T., Jun 1 2018, In : Annals of Oncology. 29, 6, p. 1402-1408 7 p.

Research output: Contribution to journal › Article

Arginine

Hepatocellular Carcinoma

Patient Care

Placebos

Survival

Small Bowel Adenocarcinoma

Chen, E. Y. & Vaccaro, G., Jan 1 2018, In : Clinics in Colon and Rectal Surgery. 31, 5, p. 267-277 11 p.

Research output: Contribution to journal › Article

Adenocarcinoma

Biliary Tract Neoplasms

Gastrointestinal Neoplasms

Delayed Diagnosis

Polyps